THCT · As filed with the SEC
THC Therapeutics income statement, by fiscal year
The statement as THC Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENT OF OPERATIONS · USD, except per-share amounts
| USD, except per-share amounts | FY2024 Year ended Jul 31, 2024 | FY2023 Year ended Jul 31, 2023 | FY2022 Year ended Jul 31, 2022 | FY2021 Year ended Jul 31, 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 |
| Operating expenses | ||||
| Professional Fees | 266,637 | 148,496 | 178,897 | 253,838 |
| Consulting fees | — | 87,170 | 966,533 | 205,170 |
| Labor and Employee Benefits | 34,543 | 187,749 | 462,317 | 267,975 |
| Selling, General and Administrative Expense | — | — | 138,281 | — |
| Selling, General and Administrative Expense | 240,795 | 70,497 | — | 212,994 |
| Total operating expenses | 541,975 | 493,912 | 1,746,028 | 939,977 |
| Loss from operations | (541,975) | (493,912) | (1,746,028) | (939,977) |
| Other income (expense) | ||||
| Non-Operating Income (Expense) | (125,444) | 184,143 | 327,501 | (393,718) |
| Interest Expense | 0 | 2,310 | — | 0 |
| Loss on sale of investment | — | — | — | 0 |
| Interest expense | (144,143) | (79,577) | (100,402) | (551,750) |
| Other Non-Cash Items (CF) | — | — | — | (945,468) |
| Total other income (expense) | — | — | 227,099 | — |
| Total other income (expense) | (269,587) | 106,876 | — | — |
| Net income (loss) | (811,562) | (387,036) | (1,518,929) | (1,885,445) |
| Basic loss per common share | — | (0.01) | — | — |
| Basic weighted average common shares outstanding | — | 32,806,009 | — | — |
| Earnings Per Share (Basic) | (0.02) | — | (0.05) | (0.08) |
| Weighted Average Shares Outstanding | 35,680,396 | — | 33,244,334 | 23,659,514 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.